0001185185-19-000251.txt : 20190215 0001185185-19-000251.hdr.sgml : 20190215 20190215134428 ACCESSION NUMBER: 0001185185-19-000251 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190215 DATE AS OF CHANGE: 20190215 EFFECTIVENESS DATE: 20190215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AngioSoma, Inc. CENTRAL INDEX KEY: 0001502152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273480481 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55072 FILM NUMBER: 19610840 BUSINESS ADDRESS: STREET 1: 2500 WILCREST DRIVE, 3RD FLOOR CITY: HOUSTON STATE: TX ZIP: 77042 BUSINESS PHONE: 832-781-8521 MAIL ADDRESS: STREET 1: 2500 WILCREST DRIVE, 3RD FLOOR CITY: HOUSTON STATE: TX ZIP: 77042 FORMER COMPANY: FORMER CONFORMED NAME: First Titan Corp. DATE OF NAME CHANGE: 20100927 NT 10-Q 1 angiosoma20190214_nt10q.htm FORM NT 10-Q angiosoma20181231_nt10k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 12b-25

 


 

NOTIFICATION OF LATE FILING

 

               

(Check one):

☐ Form 10-K

☐ Form 20-F

☐ Form 11-K

☒ Form 10-Q

☐ Form 10-D

☐ Form N-SAR

☐ Form N-CSR

 

   

 

For Period Ended: December 31, 2018

 

 

 

☐  Transition Report on Form 10-K

 

☐  Transition Report on Form 20-F

 

☐  Transition Report on Form 11-K

 

☐  Transition Report on Form 10-Q

 

☐  Transition Report on Form N-SAR

 

For the Transition Period Ended:__________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

AngioSoma, Inc.

 

Full Name of Registrant

 

 

 

2500 Wilcrest Drive, 3rd Floor

 

Address of Principal Executive Office (Street and Number)

 

 

 

Houston, TX  77042

 

City, State and Zip Code

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

The report of the registrant on Form 10-Q for the quarter ended December 31, 2018 could not be filed within the prescribed time period because the Company needs additional time to complete the financial statements and to prepare the Form 10-Q. The registrant anticipates that it will require no more than the additional 5 days allowed to complete and file the Form 10-Q.

 

PART IV — OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

 

Alex K. Blankenship

 

832

 

781-8521

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

  ☒  Yes

  ☐  No

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

  ☐  Yes

  ☒  No

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

 

 

AngioSoma, Inc.

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date

February 15, 2019

 

By

/s/ Alex K. Blankenship

 

 

 

 

Alex K. Blankenship, Chief Executive Officer